A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists
Background: Benzodiazepines and Z-drugs (e.g., zopiclone, zolpidem) (benzodiazepine receptor agonists or BZRAs), are prescribed for anxiety and insomnia disorders. However, they are not indicated as first line therapies for long-term management due to harms and efficacy limitations. BZRAs have also...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Exploratory Research in Clinical and Social Pharmacy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667276624001355 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846138167364681728 |
|---|---|
| author | Andrea L. Murphy Korolos Sawires Sophie M. Peltekian Melissa Helwig Marilyn Macdonald Ruth Martin-Misener Bandana Saini Heather Neyedli Chris Giacomantonio David M. Gardner |
| author_facet | Andrea L. Murphy Korolos Sawires Sophie M. Peltekian Melissa Helwig Marilyn Macdonald Ruth Martin-Misener Bandana Saini Heather Neyedli Chris Giacomantonio David M. Gardner |
| author_sort | Andrea L. Murphy |
| collection | DOAJ |
| description | Background: Benzodiazepines and Z-drugs (e.g., zopiclone, zolpidem) (benzodiazepine receptor agonists or BZRAs), are prescribed for anxiety and insomnia disorders. However, they are not indicated as first line therapies for long-term management due to harms and efficacy limitations. BZRAs have also been associated with traffic accident risks. Patients taking BZRAs are told to consult with health care providers regarding motor vehicle operation safety. However, advice on driving is variable. The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking BZRAs. Methods: Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) were searched. Covidence was used for screening. Each stage of screening included two independent reviewers. A REDCap database was used for data extraction by two independent reviewers. Results were tabulated and summarised as a narrative. Results: Driving performance was assessed with 20 unique BZRAs across 183 studies (n = 92 experimental; n = 91 observational) in 178 publications. Zopiclone was the most studied. In experimental studies, the Standard Deviation of Lateral Position (SDLP) was used most often (n = 54, 62 %) and many studies (n = 35, 38 %) were conducted in the Netherlands. For observational studies, biological detection (e.g., urine, blood) (n = 73, 80 %) followed by prescription drug/dispensing records (n = 17, 19 %) were the most common impairment measures and Norway (n = 20) is where most studies took place. In experimental studies, most (n = 89, 97 %) were conducted using only one driving setting. Simulated driving in a car (n = 36) and road driving in traffic (n = 36) were common as compared to nontraffic driving course (n = 8) and simulated driving (n = 9). In experimental studies, seventy-eight of the 92 studies (85 %) had at least one measure that identified impairment. Conclusions: BZRA effects on motor vehicle driving performance have been studied using heterogenous protocols with multiple measures and settings, ranging from simulation to authentic traffic situations in experimental studies to biological detection and dispensing records in observational studies. Many BZRAs have been studied but study representation does not match prescribing pattern prevalence. The interpretation and contextualization of results for clinical practice is challenging due to the complexity (i.e., protocols, measures, settings). Future work in this area should work to improve knowledge translation of results so information is more readily accessible and applicable to health care providers and patients. |
| format | Article |
| id | doaj-art-587d1be4de564b02845f1dedb0b42f3f |
| institution | Kabale University |
| issn | 2667-2766 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Exploratory Research in Clinical and Social Pharmacy |
| spelling | doaj-art-587d1be4de564b02845f1dedb0b42f3f2024-12-07T08:34:50ZengElsevierExploratory Research in Clinical and Social Pharmacy2667-27662024-12-0116100538A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonistsAndrea L. Murphy0Korolos Sawires1Sophie M. Peltekian2Melissa Helwig3Marilyn Macdonald4Ruth Martin-Misener5Bandana Saini6Heather Neyedli7Chris Giacomantonio8David M. Gardner9College of Pharmacy, Dalhousie University, Halifax, NS, Canada; Department of Psychiatry, Dalhousie University, Halifax, NS, Canada; School of Nursing, Dalhousie University, Halifax, NS, Canada; Corresponding author at: College of Pharmacy, Dalhousie University, Halifax, NS, Canada.College of Pharmacy, Dalhousie University, Halifax, NS, CanadaPharmacy Department, Nova Scotia Health Authority, Halifax, NS, CanadaWK Kellogg Health Sciences Library, Dalhousie University, Halifax, NS, CanadaSchool of Nursing, Dalhousie University, Halifax, NS, CanadaSchool of Nursing, Dalhousie University, Halifax, NS, CanadaSchool of Pharmacy, University of Sydney, Sydney, NSW, AustraliaSchool of Health and Human Performance, Dalhousie University, Halifax, NS, CanadaSociology and Social Anthropology, Dalhousie University, Halifax, NS, CanadaCollege of Pharmacy, Dalhousie University, Halifax, NS, Canada; Department of Psychiatry, Dalhousie University, Halifax, NS, CanadaBackground: Benzodiazepines and Z-drugs (e.g., zopiclone, zolpidem) (benzodiazepine receptor agonists or BZRAs), are prescribed for anxiety and insomnia disorders. However, they are not indicated as first line therapies for long-term management due to harms and efficacy limitations. BZRAs have also been associated with traffic accident risks. Patients taking BZRAs are told to consult with health care providers regarding motor vehicle operation safety. However, advice on driving is variable. The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking BZRAs. Methods: Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) were searched. Covidence was used for screening. Each stage of screening included two independent reviewers. A REDCap database was used for data extraction by two independent reviewers. Results were tabulated and summarised as a narrative. Results: Driving performance was assessed with 20 unique BZRAs across 183 studies (n = 92 experimental; n = 91 observational) in 178 publications. Zopiclone was the most studied. In experimental studies, the Standard Deviation of Lateral Position (SDLP) was used most often (n = 54, 62 %) and many studies (n = 35, 38 %) were conducted in the Netherlands. For observational studies, biological detection (e.g., urine, blood) (n = 73, 80 %) followed by prescription drug/dispensing records (n = 17, 19 %) were the most common impairment measures and Norway (n = 20) is where most studies took place. In experimental studies, most (n = 89, 97 %) were conducted using only one driving setting. Simulated driving in a car (n = 36) and road driving in traffic (n = 36) were common as compared to nontraffic driving course (n = 8) and simulated driving (n = 9). In experimental studies, seventy-eight of the 92 studies (85 %) had at least one measure that identified impairment. Conclusions: BZRA effects on motor vehicle driving performance have been studied using heterogenous protocols with multiple measures and settings, ranging from simulation to authentic traffic situations in experimental studies to biological detection and dispensing records in observational studies. Many BZRAs have been studied but study representation does not match prescribing pattern prevalence. The interpretation and contextualization of results for clinical practice is challenging due to the complexity (i.e., protocols, measures, settings). Future work in this area should work to improve knowledge translation of results so information is more readily accessible and applicable to health care providers and patients.http://www.sciencedirect.com/science/article/pii/S2667276624001355BenzodiazepinesDriving performanceSedative-hypnoticsTraffic accidentsZ-drugs |
| spellingShingle | Andrea L. Murphy Korolos Sawires Sophie M. Peltekian Melissa Helwig Marilyn Macdonald Ruth Martin-Misener Bandana Saini Heather Neyedli Chris Giacomantonio David M. Gardner A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists Exploratory Research in Clinical and Social Pharmacy Benzodiazepines Driving performance Sedative-hypnotics Traffic accidents Z-drugs |
| title | A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists |
| title_full | A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists |
| title_fullStr | A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists |
| title_full_unstemmed | A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists |
| title_short | A scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists |
| title_sort | scoping review of motor vehicle operator performance assessments for benzodiazepine receptor agonists |
| topic | Benzodiazepines Driving performance Sedative-hypnotics Traffic accidents Z-drugs |
| url | http://www.sciencedirect.com/science/article/pii/S2667276624001355 |
| work_keys_str_mv | AT andrealmurphy ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT korolossawires ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT sophiempeltekian ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT melissahelwig ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT marilynmacdonald ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT ruthmartinmisener ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT bandanasaini ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT heatherneyedli ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT chrisgiacomantonio ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT davidmgardner ascopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT andrealmurphy scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT korolossawires scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT sophiempeltekian scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT melissahelwig scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT marilynmacdonald scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT ruthmartinmisener scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT bandanasaini scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT heatherneyedli scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT chrisgiacomantonio scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists AT davidmgardner scopingreviewofmotorvehicleoperatorperformanceassessmentsforbenzodiazepinereceptoragonists |